"Johns Hopkins is one of the world's most renowned medical institutions and we're pleased to include it in our program to increase collaboration with outstanding investigator sites worldwide," said James Hamill, Group Vice President of Quintiles Accelerated Clinical Research.
"This agreement further strengthens our worldwide TotalAcceleration(TM) program to improve clinical trials while compressing drug development timelines."
The agreement with Johns Hopkins
, based in Baltimore, Md., is through its School of Medicine.Johns Hopkins Medicine
biomedical research, clinical teaching and business enterprises, and includes the Johns Hopkins University School of Medicine
, The Johns Hopkins Hospital
and several other components.The $1.8 billion enterprise is one of the largest employers in Maryland and is consistently named at the top of national rankings for best hospital and best School of Medicine.